Publication

Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers

Al-Amoud, A.L.
; 
Clark, Brian J.
; 
Assi, Khaled H.
; 
Chrystyn, Henry
Publication Date
2005
End of Embargo
Supervisor
Keywords
Bioavailability, Gentamicin, Inhalation, Lungs, Nebulizer
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Additional title
Abstract
Aims To determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers. Methods Serial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined. Results The mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) µm and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg. Conclusions The MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion.
URI
http://hdl.handle.net/10454/3430
Version
No full-text in the repository
Citation
Al-Amoud, A.L., Clark, B.J., Assi, K.H. and Chrystyn, H. (2005). Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers. British Journal of Clinical Pharmacology. Vol. 59, No. 5, pp. 542-545.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1111/j.1365-2125.2005.02360.x
Type
Article
Qualification name
Notes